A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

This phase III study is comparing a new drug combination — JS004 (an anti-CD112R antibody) plus toripalimab (an immunotherapy) — against the doctor's choice of chemotherapy in patients with classical Hodgkin lymphoma (a blood cancer) that has relapsed or stopped responding to prior immunotherapy (PD-1 or PD-L1 drugs). **You may be eligible if...** - You are 18 or older - You have been diagnosed with classical Hodgkin lymphoma that has relapsed (came back) or is refractory (did not respond) to previous treatment - You have already tried all standard treatments and your disease no longer responds to PD-1 or PD-L1 immunotherapy - You have at least one measurable tumor on imaging - You are in generally good health (ECOG 0-2) **You may NOT be eligible if...** - You permanently stopped an anti-PD-(L)1 drug due to a serious immune-related side effect - Your cancer has spread to the brain - You have fluid buildup around the lungs, heart, or abdomen requiring drainage - You have active autoimmune diseases requiring ongoing treatment with steroids or immunosuppressants Talk to your doctor to see if this trial is right for you.